DONALD L. SWEET JR., M.D.; HARVEY M. GOLOMB, M.D.; JOHN E. ULTMANN, M.D., F.A.C.P.
In this month's issue, Schein and associates (p. 417) report on their successful experience with BACOP (bleomycin, Adriamycin®, cyclophosphamide, Oncovin® [vincristine], and prednisone) combination chemotherapy in the management of patients with advanced histiocytic lymphoma. Nearly one half of previously untreated patients achieved a complete remission as defined by rigorous restaging criteria. Many of these patients may have been cured. The data of Schein and colleagues at the National Cancer Institute add substantially to the notion that malignant lymphoma, histiocytic diffuse type—once an invariably fatal disorder—is now a very treatable and perhaps curable disease. This revolution in the therapy of histiocytic
SWEET DL, GOLOMB HM, ULTMANN JE. Disseminated Malignant Lymphoma, Histiocytic Type: The Changing Picture. Ann Intern Med. ;85:521–523. doi: 10.7326/0003-4819-85-4-521
Download citation file:
Published: Ann Intern Med. 1976;85(4):521-523.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use